Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesBOM:544306 -1.60%18 PB Ratio is 10.86 as of Jul. 18, 2026, which is 32% above its 10-year median of 8.23. GuruFocus rates BOM:544306 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Sai Life Sciences ranks worse than 89.74% on this metric.
Sai Life Sciences Ltd stock PB Ratio (=10.77) is close to 1-year high of 10.79.
The historical rank and industry rank for Sai Life Sciences's PB Ratio or its related term are showing as below:
BOM:544306'
s PB Ratio Range Over the Past 10 Years
Min: 6.56 Med: 8.23 Max: 14.37
Current: 10.85
During the past 5 years, Sai Life Sciences's highest PB Ratio was 14.37. The lowest was 6.56. And the median was 8.23.
BOM:544306's PB Ratio is ranked worse than 89.74% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01
vs BOM:544306: 10.85
During the past 12 months, Sai Life Sciences's average Book Value Per Share Growth Rate was 14.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 40.10% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Sai Life Sciences was 40.10% per year. The lowest was 34.20% per year. And the median was 37.15% per year.
Back to Basics: PB Ratio
Sai Life Sciences (BOM:544306) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sai Life Sciences PB Ratio Related Terms
Sai Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sai Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sai Life Sciences (BOM:544306) has a PB Ratio of 10.86 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sai Life Sciences and its competitors. This is 32% above median its historical median of 8.23. Over the past decade, Sai Life Sciences' PB Ratio has ranged from 6.56 to 14.37. According to the industry distribution chart, Sai Life Sciences ranks #175 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 89.7%.
Is Sai Life Sciences' PB Ratio too high?
Sai Life Sciences' current PB Ratio of 10.86 is 32% above median its 10-year median of 8.23. Over the past 10 years, this metric has ranged from a low of 6.56 to a high of 14.37. The Medical Diagnostics & Research industry median PB Ratio is 2.01. Sai Life Sciences' value of 10.86 is 440.3% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #175 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #175 out of 195 companies for PB Ratio. This places Sai Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.01. Sai Life Sciences' value of 10.86 is 440.3% above this benchmark. Historically, Sai Life Sciences' own PB Ratio has ranged from 6.56 to 14.37 over the past decade. While the company's 10-year median is 8.23 vs. the industry median of 2.01, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.01, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current PB Ratio of 10.86 is 440.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current PB Ratio is 10.86, which is 32% above median its own 10-year median of 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (BOM:544306) has a current PB Ratio of 10.86. The current PB Ratio is 10.86, which is 32% above median its 10-year median of 8.23 and 440.3% above the Medical Diagnostics & Research industry median of 2.01. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sai Life Sciences (BOM:544306), the current PB Ratio is 10.86 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for BOM:544306
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544306 has been successfully added to your 
